Auxo Firm Directory · Independent Research Profile

Martis Capital

Martis Capital focuses exclusively on healthcare in North America and considers buyout and growth-equity opportunities, including minority or majority investments and recapitalizations.

Key takeaway

What stands out about Martis Capital

Martis Capital publicly targets North American healthcare opportunities with $1 – 250M+ of total enterprise value and $25 – 100M+ of total equity need. Its stated transaction approaches include buyouts, growth equity, minority or majority ownership, recapitalizations, management buyouts, strategic growth capital, and corporate carve-outs.[1][3][4][6][8]

What does Martis Capital invest in?

Martis Capital is a healthcare-focused private equity firm with offices in San Francisco, Washington, DC, and Miami. Martis Capital Management, LLC is identified by the SEC Investment Adviser Public Disclosure system as CRD #296437 / SEC #801-113653, with SEC registration effective July 19, 2018.

Martis considers buyout and growth-equity opportunities in middle-market healthcare companies. Its stated approach includes strategic planning, team and board development, operations, technology, reporting, and organic and inorganic growth.[1][2][3]

Martis describes a partnership approach with founders and management teams. It states that it may pursue minority or majority ownership, recapitalizations, management buyouts, strategic growth capital investments, and corporate carve-outs.

The firm’s stated value-creation approach includes strategic planning, team and board development, operations, technology, reporting, and organic and inorganic growth.[3][4]

Owners evaluating a financial buyer can compare the offer with independent valuation analysis, understand how acquirers approach transactions through Auxo’s buy-side M&A process guide, and consider whether a full or partial sale best fits their objectives.

Enterprise valuePublicly stated range

Lower published point$1

Upper published point$25

Published criteria: Martis publishes a target range of $1 – 250M+ total enterprise value and $25 – 100M+ total equity need.[3][6]

What should a business owner evaluate before considering a transaction with Martis Capital?

Owners evaluating Martis can compare their business against the published North American healthcare focus, the $1 – 250M+ enterprise-value range, and the $25 – 100M+ equity-need range. The stated willingness to pursue minority or majority ownership, recapitalizations, management buyouts, strategic growth capital, and corporate carve-outs provides several transaction structures for an owner to discuss.

Because the cited investment-criteria page does not state an expected investment holding period or standard exit timetable, owners should ask Martis about the anticipated investment horizon and exit process for a specific transaction. Owners should also request transaction-specific information about valuation, equity contribution, ownership and rollover expectations, governance rights, leverage, and any operating resources available for compliance, technology, recruiting, reporting, and add-on acquisitions.[3][4][6][8]

What ownership structures and rollover-equity levels are typical for the current fund

Martis states that it may pursue minority or majority ownership positions, but the cited materials do not establish the ownership or rollover terms for a specific transaction.[4]

How does Martis determine valuation and equity contribution for a specific company

Martis publishes enterprise-value and equity-need ranges, while the cited Deerfield Group announcement does not disclose transaction value or purchase-price consideration.[3][6]

What governance rights, board participation, and management incentives would apply

Martis describes partnership with founders and management teams and a value-creation approach involving team and board development; the specific governance terms for a transaction should be confirmed directly.[3][4]

What companies does Martis Capital target?

Martis publishes investment criteria of $1 – 250M+ total enterprise value and $25 – 100M+ total equity need. It describes its opportunities as buyout and growth-equity investments in middle-market healthcare companies.[3]

Martis states that it focuses on healthcare and identifies four principal subsectors: Services & Outsourcing, Information Technology, Consumer & Wellness, and Products & Diagnostics.[3]

Martis states that its geographic focus is North America. The firm identifies offices in San Francisco, Washington, DC, and Miami.[1][3]

Martis publicly describes a flexible buyout and growth-equity model and identifies corporate carve-outs among the transaction types it may pursue. Its public criteria and transaction materials cited for this profile do not establish a specific platform-versus-add-on framework.[3][4]

Martis’s official portfolio page identifies Alcanza Clinical Research, MedCap Health, ShareMD, DCN Dx, Lighthouse Lab Services, and Archway Dental Partners among its current portfolio companies. The portfolio page lists MedCap Health as a current investment dated November 2024 and classifies it within Services & Outsourcing.[5][9]

Martis Capital acquired a majority equity stake in Deerfield Group on June 30, 2026; Deerfield’s founders and management retained significant ownership interest.

Alcanza Clinical Research acquired Innovation Medical Research Center on April 9, 2024. The official announcement described that transaction as Alcanza’s ninth acquisition since 2021.

Martis Capital completed a majority recapitalization of Lighthouse Lab Services on November 1, 2021, alongside existing investor NaviMed Capital and the company’s management team.[6][7][8]

What is not clear from Martis Capital's public investment criteria?

The cited Deerfield Group transaction announcement does not disclose the transaction value, purchase-price consideration, financing terms, or detailed ownership percentages.

The cited Lighthouse Lab Services transaction announcement states that financial terms have not been disclosed.

The cited current investment-criteria page does not state an expected investment holding period or standard exit timetable.[3][6][8]

Questions to ask when evaluating Martis Capital as a buyer or investment partner

What ownership structures and rollover-equity levels are typical for the current fund?

Martis states that it may pursue minority or majority ownership positions, but the cited materials do not establish the ownership or rollover terms for a specific transaction.[4]

How does Martis determine valuation and equity contribution for a specific company?

Martis publishes enterprise-value and equity-need ranges, while the cited Deerfield Group announcement does not disclose transaction value or purchase-price consideration.[3][6]

What governance rights, board participation, and management incentives would apply?

What is the expected investment horizon and exit process?

The cited current investment-criteria page does not state an expected investment holding period or standard exit timetable.[3]

How much leverage is typically used, and what financing terms would apply?

The cited Deerfield Group transaction announcement does not disclose financing terms, so transaction-specific leverage and financing should be clarified.[6]

What operating resources are available for compliance, technology, recruiting, reporting, and add-on acquisitions?

Martis describes value-creation capabilities involving operations, technology, reporting, and organic and inorganic growth; the resources available to a particular company should be confirmed.[3]

Sources & research notes

Public-source research

Prepared and reviewed by: Auxo Capital AdvisorsEvidence standard: Public-source verification

How this profile was researched

Auxo profiles are prepared from publicly available primary and authoritative sources and reviewed for entity identity, factual support and disclosure consistency. When a fact cannot be supported by the reviewed public record, the profile identifies it as something to confirm directly rather than inferring it.

Independent profile & regulatory context

Independent research profile

This profile was prepared by Auxo Capital Advisors from publicly available information believed to be reliable and is provided solely for informational and educational purposes. It is not an endorsement, recommendation, ranking, solicitation, or representation regarding the profiled firm, its services, qualifications, transaction experience, regulatory status, financial condition, or suitability for any particular person, company, transaction, or investment.

Information obtained from third-party and public sources may be incomplete, inaccurate, outdated, or subject to change, and Auxo Capital Advisors makes no representation or warranty, express or implied, as to its accuracy, completeness, or timeliness. Readers should conduct their own independent diligence and consult appropriate professional advisers before engaging any advisor, intermediary, investor, lender, acquirer, or other transaction counterparty.

Broker-dealer and securities disclosure

Auxo Capital Advisors is an affiliate of Weild & Co., Member FINRA | SIPC. Securities-related activities and securities transactions are conducted through Weild & Co.

Nothing contained on this page constitutes an offer to sell, an offer to purchase, or a solicitation of an offer to buy or sell any security, investment product, or financial instrument. Nothing on this page constitutes investment advice, a recommendation regarding any security, or a recommendation to enter into any transaction with the profiled firm or any other party.

Any securities transaction, capital-raising engagement, investment-banking engagement, or other securities-related activity involving Auxo Capital Advisors or Weild & Co. is subject to applicable regulatory requirements, internal review and approval, suitability and other applicable diligence requirements, and the terms of a separate written engagement or transaction agreement, as applicable.

Inclusion of a third-party firm in this directory does not imply affiliation with, sponsorship by, endorsement by, or any other relationship with Auxo Capital Advisors or Weild & Co. unless expressly stated otherwise.